Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Sesen Bio stock
Own Sesen Bio stock in just a few minutes.
Sesen Bio, Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 27 staff and has a trailing 12-month revenue of around USD$11.2 million.
How to buy shares in Sesen Bio
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Sesen Bio. Find the stock by name or ticker symbol: SESN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sesen Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sesen Bio, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Sesen Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Sesen Bio share price
Use our graph to track the performance of SESN stocks over time.Sesen Bio shares at a glance
Information last updated 2021-04-09.
| 52-week range | USD$0.51 - USD$3.57 |
|---|---|
| 50-day moving average | USD$2.7688 |
| 200-day moving average | USD$1.7994 |
| Wall St. target price | USD$7 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.046 |
Buy Sesen Bio shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sesen Bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sesen Bio financials
| Revenue TTM | USD$11.2 million |
|---|---|
| Gross profit TTM | USD$-17,955,000 |
| Return on assets TTM | -17% |
| Return on equity TTM | 0% |
| Profit margin | -199.33% |
| Book value | $0.168 |
| Market capitalisation | USD$437.9 million |
TTM: trailing 12 months
Shorting Sesen Bio shares
There are currently 3.2 million Sesen Bio shares held short by investors – that's known as Sesen Bio's "short interest". This figure is 34.6% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting Sesen Bio shares can be evaluated.
Sesen Bio's "short interest ratio" (SIR)
Sesen Bio's "short interest ratio" (SIR) is the quantity of Sesen Bio shares currently shorted divided by the average quantity of Sesen Bio shares traded daily (recently around 8.2 million). Sesen Bio's SIR currently stands at 0.39. In other words for every 100,000 Sesen Bio shares traded daily on the market, roughly 390 shares are currently held short.
However Sesen Bio's short interest can also be evaluated against the total number of Sesen Bio shares, or, against the total number of tradable Sesen Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sesen Bio's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sesen Bio shares in existence, roughly 20 shares are currently held short) or 0.019% of the tradable shares (for every 100,000 tradable Sesen Bio shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sesen Bio.
Find out more about how you can short Sesen Bio stock.
Sesen Bio share dividends
We're not expecting Sesen Bio to pay a dividend over the next 12 months.
Sesen Bio share price volatility
Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.51 up to $3.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 0.6994. This would suggest that Sesen Bio's shares are less volatile than average (for this exchange).
Sesen Bio overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert